Explanatory note
(This note is not part of the Regulations)
These Regulations amend the Misuse of Drugs Regulations 2001 (S.I. 2001/3998) (“the 2001 Regulations”) and the Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015 (S.I. 2015/704) (“the 2015 Order”).
The Schedule of the 2001 Regulations in which a controlled drug is placed affects the extent to which the drug can be lawfully imported, exported, produced, supplied or possessed and dictates the controls that the drug is subject to, such as the record-keeping, labelling and destruction requirements in relation to that drug.
Section 7(3) of the Misuse of Drugs Act 1971 (c. 38) requires the Secretary of State to make regulations to allow drugs controlled under that Act to be used for medicinal purposes. Section 7(3), however, does not apply to any drug which is designated by order under section 7(4) of that Act. Controlled drugs are designated where the Secretary of State is of the opinion that it is in the public interest for production, supply and possession of that drug to be either wholly unlawful or unlawful except for research or other special purposes, or for medicinal use of the drug to be unlawful except under licence. Part 1 of Schedule 1 to the 2015 Order specifies the list of controlled drugs to which section 7(4) applies.
Regulation 2(2)(a)(i) adds twenty-one substances (four acyl piperazine opioids, two chemically bridged acyl piperazine derivatives, and fifteen novel benzodiazepines and related compounds) to Schedule 1 to the 2001 Regulations.
Regulation 2(2)(a)(ii) adds an additional common name and the full International Union of Pure and Applied Chemistry (“IUPAC”) name to the entry for methoxyphenidine, which is already included in Schedule 1 to the 2001 Regulations.
Regulation 2(2)(b) adds a range of 2-benzyl benzimidazole variants to Schedule 1 to the 2001 Regulations.
Regulation 2(3) adds xylazine to Part 1 of Schedule 4 to the 2001 Regulations.
Regulation 3(a)(i) adds the twenty-one substances added to Part 1 of Schedule 1 to the 2001 Regulations to Schedule 1 to the 2015 Order.
Regulation 3(a)(ii) adds an additional common name and the full IUPAC name to the entry for methoxyphenidine, which is already included in Part 1 of Schedule 1 to the 2015 Order.
Regulation 3(b) adds a range of 2-benzyl benzimidazole variants to Part 1 of Schedule 1 to the 2015 Order.
A full impact assessment has not been produced for this instrument as no, or no significant impact on the private sector, voluntary sector or community bodies is foreseen. An Explanatory Memorandum and an economic note are available alongside this instrument on www.legislation.gov.uk. Copies may be obtained from the Drug Misuse Unit of the Home Office at 2 Marsham Street, London, SW1P 4DF.